Ulf Mark Schneider (AP)

The cen­tral fig­ure in Nestlé's $2.6B Aim­mune buy­out? Covid-19

Nestlé sur­prised few this sum­mer when they spent $2.6 bil­lion to buy­out Aim­mune. The Swiss But­terfin­gers-and-health con­glom­er­ate had long shown more in­ter­est in them and Pal­forzia, their re­cent­ly ap­proved peanut al­ler­gy treat­ment, than any of the tra­di­tion­al Big Phar­mas.

When talks be­gan, though, in the sec­ond quar­ter, Aim­mune was on­ly look­ing for a part­ner to help them com­mer­cial­ize the ther­a­py in Eu­rope. In fact, as part of its se­ries of in­vest­ments in the com­pa­ny, Nestlé had signed a “Stand­still Agree­ment,” that would pre­vent them from ac­quir­ing the biotech un­til No­vem­ber 202o.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA